“…The structural modification and development of novel small-molecule- or monoclonal-antibody-based compounds, with affinity and selectivity towards tumor-specific receptors/markers, belong to the most prospective approaches in the diagnosis, imaging, and therapy of hypoxic tumors, and so for personalized care of oncological patients [ 5 ]. Thus, a mechanism of the catalytic activity of tumor-associated hCA isozymes in hypoxic tumors and its inhibition has been a promising target over a long period in many studies by Supuran [ 6 , 7 , 8 , 9 ], Pastorek and Pastorekova [ 10 , 11 , 12 , 13 ] working groups and in other very recently published papers [ 14 , 15 , 16 , 17 , 18 ]. Anyway, considering a broader extent of disease (also involving non-oncological ones), the inhibition of other hCA isozymes is also useful, e.g., hCA I is related to retinal and cerebral edema, hCA II to glaucoma, bone and renal diseases, edema, epilepsy, or acute high-altitude illness, and hCA IV to glaucoma, stroke, and retinitis [ 19 ].…”